Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764).

Abstract

A pilot study with the new oral long-acting neuroleptic agent clopimozide, a diphenylbutylpiperidine derivative, has been reported. 30 female patients, only 20 of whom completed the trial, were treated with dosages of between 5 and 35 mg. The treatment comprised four periods in which the maximum tolerated daily dosage, the optimal weekly dosage (mean: 20.25… (More)

Topics

Cite this paper

@article{Floru1978ClinicalEW, title={Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764).}, author={L. Floru and Julia Tegeler}, journal={Arzneimittel-Forschung}, year={1978}, volume={28 2}, pages={341-4} }